165 related articles for article (PubMed ID: 23864391)
1. Comparison of the exposure of glycyrrhizin and its metabolites and the pseudoaldosteronism after intravenous administration of alpha- and beta-glycyrrhizin in rat.
Xu R; Xiao Q; Cao Y; Yang J
Drug Res (Stuttg); 2013 Dec; 63(12):620-4. PubMed ID: 23864391
[TBL] [Abstract][Full Text] [Related]
2. 3-Monoglucuronyl-glycyrrhretinic acid is a substrate of organic anion transporters expressed in tubular epithelial cells and plays important roles in licorice-induced pseudoaldosteronism by inhibiting 11β-hydroxysteroid dehydrogenase 2.
Makino T; Okajima K; Uebayashi R; Ohtake N; Inoue K; Mizukami H
J Pharmacol Exp Ther; 2012 Aug; 342(2):297-304. PubMed ID: 22543032
[TBL] [Abstract][Full Text] [Related]
3. Effect of glycyrrhizin on cortisol metabolism in humans.
Soma R; Ikeda M; Morise T; Miyamori I; Takeda R
Endocr Regul; 1994 Mar; 28(1):31-4. PubMed ID: 7949011
[TBL] [Abstract][Full Text] [Related]
4. A possible involvement of 3-monoglucuronyl-glycyrrhetinic acid, a metabolite of glycyrrhizin (GL), in GL-induced pseudoaldosteronism.
Ohtake N; Kido A; Kubota K; Tsuchiya N; Morita T; Kase Y; Takeda S
Life Sci; 2007 Apr; 80(17):1545-52. PubMed ID: 17331546
[TBL] [Abstract][Full Text] [Related]
5. 3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism.
Kato H; Kanaoka M; Yano S; Kobayashi M
J Clin Endocrinol Metab; 1995 Jun; 80(6):1929-33. PubMed ID: 7775643
[TBL] [Abstract][Full Text] [Related]
6. 3-Monoglucuronyl glycyrrhretinic acid is a possible marker compound related to licorice-induced pseudoaldosteronism.
Makino T
Biol Pharm Bull; 2014; 37(6):898-902. PubMed ID: 24882402
[TBL] [Abstract][Full Text] [Related]
7. Administration of glycyrrhetinic acid: significant correlation between serum levels and the cortisol/cortisone-ratio in serum and urine.
Heilmann P; Heide J; Hundertmark S; Schöneshöfer M
Exp Clin Endocrinol Diabetes; 1999; 107(6):370-8. PubMed ID: 10543414
[TBL] [Abstract][Full Text] [Related]
8. Isolation of a novel glycyrrhizin metabolite as a causal candidate compound for pseudoaldosteronism.
Morinaga O; Ishiuchi K; Ohkita T; Tian C; Hirasawa A; Mitamura M; Maki Y; Yasujima T; Yuasa H; Makino T
Sci Rep; 2018 Oct; 8(1):15568. PubMed ID: 30348944
[TBL] [Abstract][Full Text] [Related]
9. A semi-physiologically based pharmacokinetic pharmacodynamic model for glycyrrhizin-induced pseudoaldosteronism and prediction of the dose limit causing hypokalemia in a virtual elderly population.
Xu R; Liu X; Yang J
PLoS One; 2014; 9(12):e114049. PubMed ID: 25463381
[TBL] [Abstract][Full Text] [Related]
10. Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study.
Takahashi K; Yoshino T; Maki Y; Ishiuchi K; Namiki T; Ogawa-Ochiai K; Minamizawa K; Makino T; Nakamura T; Mimura M; Watanabe K
Arch Toxicol; 2019 Nov; 93(11):3111-3119. PubMed ID: 31605160
[TBL] [Abstract][Full Text] [Related]
11. [The inhibitory effects of glycyrrhizin and glycyrrhetinic acid on the metabolism of cortisol and prednisolone--in vivo and in vitro studies].
Ojima M; Satoh K; Gomibuchi T; Itoh N; Kin S; Fukuchi S; Miyachi Y
Nihon Naibunpi Gakkai Zasshi; 1990 May; 66(5):584-96. PubMed ID: 2384181
[TBL] [Abstract][Full Text] [Related]
12. Exploration for the real causative agents of licorice-induced pseudoaldosteronism.
Makino T
J Nat Med; 2021 Mar; 75(2):275-283. PubMed ID: 33481180
[TBL] [Abstract][Full Text] [Related]
13. Risk factors associated with pseudoaldosteronism in patients with chronic hepatitis: A retrospective cohort study.
Komatsu A; Yoshino T; Suzuki T; Nakamura T; Kanai T; Watanabe K
Basic Clin Pharmacol Toxicol; 2019 May; 124(5):607-614. PubMed ID: 30471199
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney.
Kageyama Y; Suzuki H; Saruta T
J Endocrinol; 1992 Oct; 135(1):147-52. PubMed ID: 1431677
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of glycyrrhizin from Shaoyao-Gancao-Tang in laxative-treated rats.
Goto E; He JX; Akao T; Tani T
J Pharm Pharmacol; 2005 Oct; 57(10):1359-63. PubMed ID: 16259766
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the antihepatotoxic activity between glycyrrhizin and glycyrrhetinic acid.
Nose M; Ito M; Kamimura K; Shimizu M; Ogihara Y
Planta Med; 1994 Apr; 60(2):136-9. PubMed ID: 8202565
[TBL] [Abstract][Full Text] [Related]
17. Final report on the safety assessment of Glycyrrhetinic Acid, Potassium Glycyrrhetinate, Disodium Succinoyl Glycyrrhetinate, Glyceryl Glycyrrhetinate, Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and Potassium Glycyrrhizinate.
Cosmetic Ingredient Review Expert Panel
Int J Toxicol; 2007; 26 Suppl 2():79-112. PubMed ID: 17613133
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury.
Makino T; Ohtake N; Watanabe A; Tsuchiya N; Imamura S; Iizuka S; Inoue M; Mizukami H
Drug Metab Dispos; 2008 Jul; 36(7):1438-43. PubMed ID: 18362159
[TBL] [Abstract][Full Text] [Related]
19. Correlation between high intake of glycyrrhizin and myolysis of the papillary muscles: an experimental in vivo study.
Rossi T; Fano RA; Castelli M; Malagoli M; Ruberto AI; Baggio G; Zennaro R; Migaldi M; Barbolini G
Pharmacol Toxicol; 1999 Nov; 85(5):221-9. PubMed ID: 10608484
[TBL] [Abstract][Full Text] [Related]
20. Glycyrrhizin and licorice significantly affect the pharmacokinetics of methotrexate in rats.
Lin SP; Tsai SY; Hou YC; Chao PD
J Agric Food Chem; 2009 Mar; 57(5):1854-9. PubMed ID: 19209930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
